With the 2019 ASCO convention a few weeks away, we’re highly anticipating all the new data to be presented and deciding which sessions to attend. This year’s theme is Caring for Every Patient, Learning from Every Patient, so plan on a good dose of patient-centric sessions.

ASCO recently announced several top studies to be presented this year, including new approaches to overcoming limited access to cancer care. We eagerly await more news regarding sessions on advances in targeted therapies for pancreatic, prostate, and pediatric cancers, as well as reviews of the many advancements in precision medicine.

Additional top research being released includes:

  • Metastatic hormone-sensitive prostate cancer – a randomized, phase III trial evaluating the impact of adding enzalutamide to standard initial treatment
  • Advanced soft tissue sarcomas – a randomized, phase III trial comparing olaratumab plus doxorubicin versus doxorubicin alone
  • Pancreatic cancer with inherited BRCA gene mutation – a randomized, phase III trial exploring maintenance therapy with the PARP inhibitor olaparib
  • Multiple myeloma – analysis of whether private insurance and regional income impacts survival
  • Advanced NSCLC – study of the potential impact of new strategies to expand patient eligibility for clinical trials
  • mNSCLC – five-year survival data from the KEYNOTE-001 trial (safety and effectiveness of pembrolizumab)

To review the full list of top studies to be presented, click here.

We look forward to seeing you May 31 – June 4 in Chicago. If you’d like to set up a meeting to discuss how Beacon can assist you with your communications needs, or just to compare notes over a cup of coffee, email shibbard@BeaconHC.com.

More news